In the event the expanding range of pre-clinical science transfers into positive, conformational clinical results, I would not be disappointed if any sale to BP discounted initial purchase price for a high rate royalty.
With projected spending for oncology by 2026 at over US$300b, results anywhere near the TAM percentages for Zantrene would a great ROI.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)